Multiple Sclerosis and Related Disorders

Papers
(The median citation count of Multiple Sclerosis and Related Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis70
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis67
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study61
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS57
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis55
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients54
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry51
Impact of insurance status on MRI phenotypes in MS50
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects44
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports43
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran41
Lipid measures are associated with cognitive functioning in multiple sclerosis patients41
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease39
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis39
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America39
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)37
Involvement Peripheral Nerve System in Multiple Sclerosis36
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study35
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study35
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod35
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study34
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study34
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk34
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?33
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan33
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?33
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination33
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina30
A critical evaluation of machine learning approaches for screening depression and anxiety in early multiple sclerosis30
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review29
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial29
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience29
Nutritional status and taste impairment in adult patients with multiple sclerosis and dysphagia. A pilot study28
Cardiorespiratory response to different aerobic exercise modalities in people with advanced multiple sclerosis28
Post-infusion observation of patients with multiple sclerosis receiving natalizumab: Is it necessary?28
AQP4-IgG positive and AQP4-IgG–negative NMOSD: A Multicenter Latin-American Cohort vs. a Single-Center Argentine Cohort28
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis28
Transcranial magnetic stimulation outcomes as biomarkers of multiple sclerosis disease progression: A structured literature review28
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis28
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis28
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series27
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul27
Effects of Respiratory Muscle Training on Respiratory Function and Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis27
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study27
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review27
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis27
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya26
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography26
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease26
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life25
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis25
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis25
How Much Is Enough? Determining Minimum Valid Tracking Periods for Reliable Physical Activity Monitoring25
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology24
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort24
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis24
Real-World Outcomes of Cladribine in People ≥55 years of age with Multiple Sclerosis24
Sexual problems in MS: Sex differences and their impact on quality of life24
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms24
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study23
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u23
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD23
Using MS induced pluripotent stem cells to investigate MS aetiology23
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis23
Cladribine effects on emotional awareness and reasoning: The CLEAR study22
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis22
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management22
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis22
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis22
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients22
More questions than answers: Why is cognitive dysfunction associated with less use of evidence-based psychotherapy in multiple sclerosis?22
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience22
Impact of multiple sclerosis on male sexual and reproductive health21
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis21
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers21
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia21
Cognition beyond relapses: cognitive progression independent of relapse activity reflects early smoldering neurodegeneration in multiple sclerosis21
A systematic review and meta-analysis on gene-environment interaction effects on the associations of vitamin D and sun exposure with multiple sclerosis risk21
Aging does not affect the relationship between OCT and clinical or MRI outcome measures21
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital20
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery20
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder20
41. Neuropathic Pain in Multiple Sclerosis20
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System20
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series20
81. Gender Difference In Egyptian Patients With Multiple Sclerosis20
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis20
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab20
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients20
Cervical lymph node diameter reflects disease progression in multiple sclerosis19
Telehealth in Multiple Sclerosis: Fostering Quality of Life19
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model19
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study19
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background19
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography19
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD19
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis19
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up19
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study19
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey19
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis19
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment19
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis18
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm18
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study18
Perspectives on fatigue management among veterans living with multiple sclerosis18
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review18
Monkeypox in Multiple Sclerosis patients: Should we be alert?18
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)18
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul18
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study18
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan18
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters18
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study18
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review18
Adherence to Treatment in Multiple Sclerosis17
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging17
Carotid intima media thickness and multiple sclerosis17
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review17
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study17
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil17
Multiple sclerosis and related disorders multiple sclerosis across Isfahan Province, Iran: Urban–rural disparities and no association with air quality measures17
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis17
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis17
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis17
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review17
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial17
Inter-assay variability in anti–JC virus testing for natalizumab: A Spanish cohort17
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study17
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study17
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study17
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?17
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool17
Significant upregulation of prenyltransferase-related genes in neuromyelitis optica: Diagnostic potential and clinical correlations17
Multiple sclerosis and uveitis: Clinical characteristics and prognosis17
Low intensity interval robot-assisted gait training improves mobility in people with progressive multiple sclerosis: the PROGR-EX randomized controlled trial16
Glial-mediated pathogenesis and intervention strategies in neuromyelitis optica spectrum disorder16
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial16
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries16
MS in the UAE: Population Estimates of Anxiety, Depression and Health-Related Quality of Life16
Comparison of vision-related quality of life in NMOSD and MOGAD16
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis16
Efficacy and safety of ocrelizumab in pediatric multiple sclerosis16
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)16
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract16
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202116
Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study16
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects16
Effects of inspiratory muscle training on balance, trunk control, fear of falling, respiratory function, and quality of life in people with multiple sclerosis: a randomized controlled trial16
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database16
Multiple Sclerosis and biological definitions in neurodegenerative diseases16
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco16
Reduced physical activity in multiple sclerosis: The role of gait parameters, gait variability parameters and self-reported measure of gait16
Beyond the B-cell as a treatment target in multiple sclerosis15
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain15
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care15
Racial disparities in hypertension management among multiple sclerosis patients15
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison15
Linking X to MS: Immunity and demyelination on the X-chromosome in MS15
The effect of cooling garments to improve physical function in people with multiple sclerosis: A systematic review and meta-analysis15
Emerging trends in multiple sclerosis research15
Systematic review on the wearing-off phenomenon of disease-modifying therapies in managing multiple sclerosis15
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis15
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis15
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis15
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis15
Seizures in inflammatory demyelinating disorders of the central nervous system15
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review15
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy15
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis15
Deciphering the bidirectional impact of leukocyte telomere length on multiple sclerosis progression: A Mendelian randomization study15
Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare15
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges15
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon15
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants15
Increased healthcare utilization in the year before multiple sclerosis diagnosis15
Efficacy of caffeine supplementation on fatigue in patients with multiple sclerosis: A randomized double-blind placebo-controlled trial15
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal15
Unwrapping the “black box” of balance training in people with multiple sclerosis – A descriptive systematic review of intervention components, progression, and intensity14
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis14
Serum Oxidative Stress Biomarkers in Relapsing Remitting Multiple Sclerosis Patients with No Evidence of Disease Activity14
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.14
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity14
Bridging perspectives on comorbidities in multiple sclerosis: A pilot study with individuals with lived experience and healthcare professionals14
A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy14
Additive beneficial effects of aerobic training and royal jelly on hippocampal inflammation and function in experimental autoimmune encephalomyelitis rats14
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis14
Are we ready for CD19-targeted CAR T-cell therapies in MS?14
Serum Neurofilament Light Chain as a Biomarker of Disease Progression in a Sample of Egyptian Multiple Sclerosis Patients14
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences14
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients14
Distinct microstructural white matter alterations in demyelinating diseases: Insights from myelin- and axon-sensitive MRI14
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study14
Bone loss and fracture in people with multiple sclerosis: A systematic review and meta-analysis14
Social network size and mental health outcomes in youth with neuroinflammatory disorders14
Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response14
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes14
S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th14
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes14
Assessment of changes in fatigue and cognitive functioning in the absence of progression independent of relapse activity14
Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials14
Physical activity is associated with fatigue in persons newly diagnosed with multiple sclerosis14
Efficacy of traditional swallowing therapy plus neuromuscular electrostimulation in multiple sclerosis: A randomized controlled trial13
Prevalence and incidence of multiple sclerosis in the Netherlands13
Evaluating the impact of systematic reporting of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial13
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis13
Sleep, physical activity, and psychological outcomes in children and adolescents with pediatric onset multiple sclerosis13
The Association of ApoE Genotype and Cognitive Impairment in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis13
148. Correlations Between Cognitive Impairment and Multiple Sclerosis Treatments13
Mitochondrial DNA Copy Number as a Biomarker of Multiple Sclerosis13
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)13
Feasibility and tolerability of portable, low-field brain MRI for patients with multiple sclerosis13
153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial13
Association between breastfeeding and multiple sclerosis: A literature review13
Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap in Patient with Multiple Sclerosis Treated with Ocrelizumab: A Case Study and Literature Review13
Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection13
Validation of a new diagnostic ELISA to detect anti-JCV antibodies in serum of patients with multiple sclerosis considering or receiving treatment with natalizumab13
Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders13
Burden of multiple sclerosis: impact on the patient, family and society13
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis13
Optic Nerve Imaging Solving Demyelination Mystery13
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis13
31. Quantitative susceptibility mapping (QSM)-based regional iron concentration: Does it correlate with brain volume loss? An analysis of 250 regions of interest (ROIs)13
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients13
Cognitive performances in people with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis13
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis13
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis13
Prognosis of walking function in multiple sclerosis supported by gait pattern analysis13
Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease13
Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice13
MRI-based radiomics for differention of aquaporin 4-immunoglobulin G–positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder13
Effects of six-month home-based neuro-functional and resistance training interventions on cognitive and motor performance in multiple sclerosis patients with cognitive impairment: A randomized control13
44. Breaking Free from the Six-Month Cycle13
The Impact of Bladder Dysfunction on Physical Activity in Multiple Sclerosis Using Wearable Technology13
Understanding use and predictors of compensatory cognitive strategies in people with multiple sclerosis13
The influence of manual dexterity on processing speed assessment in multiple sclerosis: A comparison of the PST and oral SDMT13
Patient-reported quality of life and perceived disease burden in mexican patients with neuromyelitis optica spectrum disorder: a cross-sectional analysis13
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS13
Therapeutic plasma exchange in Myelin oligodendrocyte glycoprotein associated disorders-an ambispective study13
Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction12
Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection12
A pilot study comparing myelin measurements from myelin water imaging and 11C-PIB PET in multiple sclerosis12
Sex differences in multiple sclerosis treatment with disease modifying drugs: a step towards gender neurology12
Consultation in Patients with Multiple Sclerosis12
Adherence to Disease Modifying Treatment Among Multiple Sclerosis Patients from Upper Egypt12
Alemtuzumab-induced thyroid disease: A Danish cohort study12
Treatment of Multiple Sclerosis as a single disease based on the body-pathology-environment model12
Comment on “prevalence and risk factors of dysphagia in patients with multiple sclerosis”12
What If It Is not Optic Neuritis?12
Knowledge and worries on motherhood choice in multiple sclerosis – a cross-sectional study on patient-reported outcome measures12
0.078495979309082